Tag: wegovy price in india

Ozempic went viral for helping people lose weight after being introduced as a diabetes injection in 2018. (AP)
Posted in Business

Opinion | Why Generic Ozempic is a game changer for China and India

The simultaneous patent expiry of Ozempic’s active ingredient in China and India on Friday is a watershed moment. Until now, the revolutionary weight-loss drugs have…

Continue Reading
Pharmarack estimates India’s weight-loss drug market to surge from roughly  ₹1,500 crore today to  ₹8,000 crore by 2030. (Reuters)
Posted in Business

Indian Pharma is ready to flex generics muscle as Ozempic, Wegovy patent expires today| Business News

India’s pharma industry is ready to flex its generics muscle as the patent for a key ingredient of blockbuster weight-loss drugs expires today. Pharmarack estimates…

Continue Reading
Mankind Pharma, Ajanta Pharma, Sun Pharma, Dr. Reddy’s and Lupin are gearing up to sell generic versions of Semaglutide, the molecule behind the blockbuster Ozempic weight-loss drug. (AP)
Posted in Business

Prices of weight-loss drugs set to halve in India as Ozempic patent expires this week| Business News

Swati Pradhan sees about 12 obesity patients a day at her small clinic in southern Mumbai. She expects this number to at least double from…

Continue Reading
Novo Nordisk slashed WeGovy prices by up to 37% in India last month. (Reuters)
Posted in Business

After India, Novo Nordisk cuts WeGovy price in China on generics challenge| Business News

Novo Nordisk AS is lowering prices of its top-selling WeGovy weight-loss drug in China, as the Danish drugmaker braces for intense competition from local rivals…

Continue Reading
Novo Nordisk will sell Poviztra 2.4 mg semaglutide injection in India as a separate brand of its blockbuster weight-loss drug WeGovy. (Reuters)
Posted in Business

Novo Nordisk cuts Wegovy price in India by up to 37% in rivalry with Eli Lilly’s Mounjaro| Business News

Novo Nordisk A/S has cut the prices its weight-loss drug Wegovy by up to 37% in India, as the Danish drugmaker looks to hold its…

Continue Reading